Saturday, October 3, 2026

BTC $84,570 ▼ 2.18%

NewsLive Wire Politics World Markets Digital Assets Technology Sports

FranchisesThe Brief The Big Read The Breakdown Crypto Culture

MoreDeFi & On-Chain U.S. Equities Macro & Rates Research

LIVE

BTC$84,570−2.18%ETH$2,677−1.99%SOL$119.38−2.86%XRP$1.49−2.19%LINK$13.98−3.72%ADA$0.246−3.16%S&P 5007,723+0.73%Nasdaq27,191+1.19%Dow51,177+0.49%RUT2,833+0.94%TNX5.28%+0.76%TYX5.63%+0.48%FVX5.05%+1.00%IRX3.99%+0.28%VIX15.31−6.59%GOLD$4,162.30−0.95%SILVER$60.42−1.24%OIL$91.11−1.90%DXY101.92−0.01%NVDA$233.95+1.34%AAPL$333.69+1.02%TSLA$370.59+4.65%META$728.08+0.30%MSFT$517.53+0.92%AMZN$251.52+1.33%GOOGL$343.50+1.56%Fear & Greed67 — GreedBTC$84,570−2.18%ETH$2,677−1.99%SOL$119.38−2.86%XRP$1.49−2.19%LINK$13.98−3.72%ADA$0.246−3.16%S&P 5007,723+0.73%Nasdaq27,191+1.19%Dow51,177+0.49%RUT2,833+0.94%TNX5.28%+0.76%TYX5.63%+0.48%FVX5.05%+1.00%IRX3.99%+0.28%VIX15.31−6.59%GOLD$4,162.30−0.95%SILVER$60.42−1.24%OIL$91.11−1.90%DXY101.92−0.01%NVDA$233.95+1.34%AAPL$333.69+1.02%TSLA$370.59+4.65%META$728.08+0.30%MSFT$517.53+0.92%AMZN$251.52+1.33%GOOGL$343.50+1.56%Fear & Greed67 — Greed

Tag

NVO

3 articles

U.S. Equities1h ago

Novo Nordisk's Denecimig Delayed to 2027; FDA Manufacturing Review Extends Timeline

Novo Nordisk said the FDA extended its review of denecimig for hemophilia A due to manufacturing site remediation, pushing the expected U.S. launch into 2027.

U.S. Equities2h ago

Novo Nordisk Delays Denecimig US Launch to H1 2027 on Manufacturing Issues

FDA manufacturing facility concerns push haemophilia A treatment past original 2026 target; clinical data deemed acceptable

U.S. Equities18d ago

Novo Nordisk Rebrands to 'Novo' as GLP-1 Wars Heat Up

The pharmaceutical giant streamlines its identity ahead of intensifying competition with Eli Lilly in obesity and diabetes markets.